Explores the use of infliximab and other similar biologics for use in patients with Ulcerative Colitis, luminal Crohn's Disease and fistulizing Crohn's disease. This title reviews the perceived mechanisms of action, and adverse events and similar agents under investigation. It is suitable for gastroenterologists, surgeons, and family physicians.

Gastroenterologists, surgeons, family physicians, gynecologists, internists, medical students, nurses and all other health care deliverers who are caring for patients with Inflammatory bowel disease must have this issue because it focuses is on clinically relevant topics, patient management issues; laboratory-based investigations will be touched upon with a translational focus. Key words of this title include: Biologics, Infliximab, monoclonal antibody, Crohn's Disease, Fistulae, Ulcerative Colitis, Refractory Crohn's Disease, novel therapy, economics, fistulae, luminal Crohn's disease, and infusion reactions.